BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Pfizer

Investors appear to be seeing a future where COVID-19 vaccines aren't needed nearly as much.

Why Pfizer, BioNTech, and Moderna Stocks Are Falling Today

The agency also greenlights a booster for younger children who are immunocompromised.

FDA authorizes COVID boosters for kids ages 12 to 15

The new approval comes as the Omicron variant surges through the US, driving up new COVID-19 cases to record highs.

FDA approves Pfizer's COVID-19 vaccine booster shot for children ages 12 and up

Pfizer Inc. PFE, -3.95% and BioNTech SE BNTX, -4.93% announced Monday that the U.S. Food and Drug Administration has granted Emergency Use Authorization of a booster dose of the companies' COVID-19 vaccine into people ages 12 years and older. Previously, the FDA had only authorized a booster for people aged 16 years and older.

Pfizer, BioNTech booster shot EUA expanded to include children 12 years old

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 12 years of age and older. The booster dose is the same dosage strength (30-µg) as the dose approved in the primary series. A booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorize

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older

New Covid infections have hit a pandemic high in the U.S. as the highly contagious omicron variant has supplanted delta as the dominant strain.

FDA expands Pfizer booster eligibility to kids ages 12 to 15

One coronavirus vaccine will apparently be authorized as a booster for younger people in the U.S.

Why Pfizer, BioNTech, and Moderna Shot Higher Today

Vaccine stocks have been in a recent downfall, and getting hit particularly hard are Moderna Inc (NASDAQ:MRNA) and BioNTech SE (NASDAQ:BNTX).

Vaccine Sector Rally Over for These 2 Stocks

MAINZ, Germany, December 27, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 9:45 am ET.

BioNTech to Present at the 40th Annual J.P. Morgan Healthcare Conference

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have submitted longer-term follow-up data from the Phase 3 trial of the COVID-19 mRNA vaccine in adolescents to the European Medicines Agency (EMA). The data from 2,228 individuals 12 through 15 years of age aims to support further the favorable safety and efficacy profile of Comirnaty in this age group.

Pfizer-BioNTech Reveals Updated Longer-Term Data On COVID-19 Shot In Adolescents

Dynavax Technologies

Intellia Therapeutics

Prothena

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.

5 Biotech Stocks That More Than Doubled This Year

Novavax

Ocugen, Inc.

Decreasing concerns about the omicron variant are leading to declining prices for these vaccine stocks.

Why BioNTech, Novavax, and Ocugen Stocks Are Slipping Today

It had much to do with a certain Greek letter.

Why Some Coronavirus Stocks Plunged Today

Vaccine stocks aren't enjoying a good morning today, but there's plenty of reason to suspect that they are in for a better year in 2022. The post MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?

MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement has been reached with the European Commission (EC) and its member states to exercise an option to purchase more than 200 million additional doses of COMIRNATY®, the companies' COVID-19 vaccine. Contractual details are currently being finalized. These 200 million optional doses are in addition to the 450 million doses already planned to be delivered in 2022 based on pre

Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply

Pfizer Inc. PFE, -2.89% and German partner BioNTEch SE BNTX, +1.27% said Monday they have reached an agreement to provide an additional 200 million doses of their COVID-19 vaccine to the European Commission and its member states in 2022. The companies said the 200 million doses are on top of 450 million that are already planned for delivery in 2022 in previous contracts.

Pfizer and BioNTech to provide more than 200 million additional COVID vaccine doses to EU in 2022

Eli Lilly

Don't expect the momentum to dwindle for these stocks.

3 Biotech Stocks That Soared in 2021 and Could Go Even Higher in 2022

BioNTech SE (BNTX) is one of the biggest beneficiaries of the pandemic, as it launched the German company to global success while reporting record revenues quarter after quarter in FY2021. With the billions earned from Comirnaty, BNTX is accelerating its oncology and infectious diseases pipeline for regulatory approval within the next five years.

BioNTech Has More To Give Than Just Its COVID-19 Vaccine

All of these vaccine stocks benefited from rising concerns about the Omicron variant.

Why Novavax, BioNTech, and Moderna Stocks Are Jumping This Week

The Omicron variant has made Wuhan based vaccines redundant, will replace Delta, and causes a milder version of covid. BioNTech, Novavax and Moderna will need to urgently develop an appropriate 2nd generation vaccine candidate.

COVID-19 Vaccines: The Big Omicron Reboot For BioNTech, Moderna And Novavax

A new private study by South Africa's Discovery Health suggests that Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine is just 33% effective against infections by the omicron variant. However, the Company reported that the variant appears to cause less severe disease.

South African Study Shows Omicron Variant Could Escape Pfizer/BioNTech COVID-19 Vaccine Protection

The study didn't confirm all cases were Omicron, although the variant caused 70% of infections in the past month, according to health officials.

Two doses of Pfizer's vaccine cut the risk of hospitalization by 70% during Omicron surge, real-world data from South Africa showed

The preliminary findings suggest a big drop in protection against infection with omicron but strong (70%) protection against hospitalization.

Pfizer Shot Just 33% Effective Against Omicron Infection, But Largely Prevents Severe Disease, South Africa Study Finds

Two shots of the COVID vaccine produced by Pfizer PFE, +4.59% and BioNTech BNTX, +7.97% may offer 70% protection against hospitalizations due to the omicron variant, a South African study showed Tuesday, Bloomberg reported. The study was released by Discovery Ltd.

News for BioNTech SE Stock (BNTX)